• PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
    • indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth
    • PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency
    PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
    PRISM Q & A Corner

    PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

    NEW YORK, December 19, 2024 - PRISM MediaWire - PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III ...
    indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth
    PRISM View

    indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth

    New York, November 11, 2024 - PRISM MarketView - indie Semiconductor (NASDAQ: INDI) reported Q3 2024 revenue of $54 million, reflecting a 3.1% sequential increase but an 11% decline compared to the same period in 2023. Despite a challenging automotive market, the company...
    PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency
    PRISM View

    PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency

    New York, November 08, 2024 - PRISM MarketView - The electric vehicle (EV) landscape in the U.S. is facing a critical moment of potential policy change and industry recalibration following the victory of President-elect Donald Trump over Vice President Kamala Harris. Wit...
    PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
    indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth
    PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency
    PRISM Q & A Corner
    PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

    NEW YORK, December 19, 2024 - PRISM MediaWire - PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III ...

    19 December 2024

    PRISM View
    indie Semiconductor Defies Industry Headwinds with Strong Q3 Performance and Strategic ADAS Wins, Sets Sights on Accelerated Growth

    New York, November 11, 2024 - PRISM MarketView - indie Semiconductor (NASDAQ: INDI) reported Q3 2024 revenue of $54 million, reflecting a 3.1% sequential increase but an 11% decline compared to the same period in 2023. Despite a challenging automotive market, the company...

    11 November 2024

    PRISM View
    PRISM EV Index: Navigating Uncertainty as Lucid, Rivian, and Blink Chart Their Course Amid Trump Presidency

    New York, November 08, 2024 - PRISM MarketView - The electric vehicle (EV) landscape in the U.S. is facing a critical moment of potential policy change and industry recalibration following the victory of President-elect Donald Trump over Vice President Kamala Harris. Wit...

    8 November 2024

    PRISM Latest
    MNMD Q3 Snapshot: Advancing Three Phase 3 Trials with Ample Cash

    New York, November 08, 2024 - PRISM MarketView - MindMed (NASDAQ: MNMD) reported its third quarter 2024 financial results and provided significant business updates, highlighting its progress towards initiating multiple Phase 3 clinical trials for its lead candidate, MM12...

    8 November 2024

    PRISM Cannabis
    Earnings Burnout: Canopy Growth Reports Q2 Revenue Drag From Canadian Adult Use Segment

    New York, November 08, 2024 - PRISM MarketView - Canadian cannabis company, Canopy Growth Corporation (CGC), announced its second quarter financials and posted revenues of C$47.1M which were down 4.3% year-over-year (y/y). This loss is attributed to a (23.7%) y/y decline...

    8 November 2024

    PRISM View
    Got Oatly? Q3 Financial Results Show Revenue Growth Across All Geographic Markets

    New York, November 07, 2024 - PRISM MarketView Today the oat milk producer Oatly (OTLY) has announced its Q3 financial results that illustrate year-over-year revenue growth across all of its geographic markets. Its Europe & International posted at $109.9M vs year-ago...

    7 November 2024

    PRISM View
    You Can Call It a Comeback: Townsquare Media Net Revenue Returns to Year-Over-Year Growth

    New York, November 07, 2024 - PRISM MarketView - PRISM AdTech and Media Index company Townsquare Media (TSQ) posted its third quarter results that included returning to year-over-year growth across each of its three business segments. Its Digital segement represented 52%...

    7 November 2024

    PRISM Biotech
    Cingulate Reports Strong Q3 with $19.5M Boost to Propel ADHD Platform, Eyes Mid-2025 NDA Submission

    New York, November 07, 2024 - PRISM MarketView - Cingulate Inc. (Nasdaq: CING) reported a $19.5 million increase in working capital in Q3 2024, strengthening its financial position to advance its lead ADHD asset, CTx-1301, toward a mid-2025 New Drug Application (NDA) sub...

    7 November 2024

    PRISM Cannabis
    Could Tilray Medical’s Cannabis Extract Be a Breakthrough for Chemotherapy-Induced Nausea and Vomiting? Promising Report Revealed

    New York, November 07, 2024 - PRISM MarketView - Tilray Medical (NASDAQ: TLRY) has announced positive findings from a study examining the use of an oral cannabis extract for treating chemotherapy-induced nausea and vomiting (CINV). This condition, affecting up to 80% of ...

    7 November 2024

    PRISM View
    Wheelin and Dealin: Cerence and Kawasaki Partner to Provide AI Assistance to Riders

    New York, November 06, 2024 - PRISM MarketView - The AI mobility experience leader Cerence, Inc. (CRNC) has announced a partnership with Kawasaki Motors to enhance user experience across its two-wheeled vehicles. Kawasaki intends to integrate Cerence Ride into its two wh...

    6 November 2024

    Social Media
    Press Kit

    See More

    PRISM Emerging Biotech Index

    PRISM Emerging Cannabis

    PRISM Emerging Consumer Products

    PRISM Emerging EV

    PRISM MarketView

    Founded in 2020, PRISM MarketView focuses on providing analysis and monitoring of small cap stocks in emerging sectors. PRISM MarketView offers current financial market news and commentary alongside a range of tools for investors. We specialize in creating and managing proprietary indexes that track sectors such as biotech, oil and gas, new energy, medical devices and more. 

    Our mission is to provide information and insights to empower investors in making informed decisions. Through PRISM MarketView, investors have access to the latest news and data, helping them stay informed about market trends and opportunities. 

    Join us in exploring the dynamic world of investing!


    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.